Dr Robert J. Motzer is the Kidney Cancer Section Head of the Genitourinary Oncology Service and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and a Professor of Medicine at Weill Cornell Medical College in New York, New York. He earned his medical degree from the University of Michigan Medical School in Ann Arbor Michigan before completing an internal medicine residency at the Cornell University Medical College Affiliated Hospitals and a fellowship in hematology/oncology at MSKCC. Additionally, Dr Motzer serves as and Chairman of the National Comprehensive Cancer Network Kidney Cancer Guidelines Panel.
For over 30 years, Dr Motzer has dedicated his clinical and research efforts to improving the lives of people with genitourinary cancer. His primary area of expertise is renal cell carcinoma (RCC), particularly metastatic disease or disease that is at high risk of becoming metastatic. He has led over 75 clinical trials in RCC and testicular cancer, including national and international multicenter trials. Dr Motzer’s research has helped identify 9 ground-breaking targeted agents that are effective for advanced RCC. He also developed the Motzer System, a risk algorithm based on clinical and laboratory data that aids in the prediction of treatment outcomes for patients taking medications for advanced RCC, which has been used in patient selection for clinical trials. Dr Motzer has published more than 500 scientific articles, reviews, and chapters, and has been invited to deliver lectures nationally and internationally.